AstraZeneca enters major AI drug discovery partnership with Insitro
AstraZeneca has partnered with biotechnology company Insitro in a deal valued at up to $1.5 billion to discover novel drugs. The collaboration leverages artificial intelligence to target cardiovascular and liver diseases.
